NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Apollo Hospitals Q3 FY26: Consolidated PAT Surges 170% YoY to ₹5,023 Million
Apollo Hospitals Enterprise Limited reported a robust performance for Q3 FY26, with consolidated revenue growing 17% YoY to ₹64,774 million. The company's bottom line saw a massive jump, with PAT increasing 170% YoY to ₹5,023 million, driven by strong operational performance across all business verticals. The core Healthcare Services segment maintained healthy EBITDA margins of 24.8%, while the Apollo HealthCo and AHLL segments both recorded 20% revenue growth, signaling strong momentum in digital health and retail clinics.
முக்கிய அம்சங்கள்
Consolidated Revenue increased by 17% YoY to ₹64,774 million in Q3 FY26.Consolidated PAT witnessed a significant 170% YoY surge, reaching ₹5,023 million.Healthcare Services (Hospitals) reported an EBITDA margin of 24.8% with 67% occupancy.Apollo HealthCo (Digital & Pharmacy) revenue grew 20% YoY to ₹28,274 million with 7,113 outlets.Retail Health (AHLL) EBITDA grew by 39% YoY to ₹476 million, reflecting improved profitability.
👀 கவனிக்க வேண்டியவை
Investors should take note of the significant margin expansion and the massive jump in PAT, which indicates strong operational efficiency. The continued growth in the digital health platform (Apollo 24|7) and the pharmacy network strengthens the company's long-term competitive position.
Apollo Hospitals Subsidiary Acquires Belenus Champion Hospitals for Rs 1,650 Million
Apollo Hospitals' subsidiary, Imperial Hospital and Research Centre Limited, has completed the 100% acquisition of Belenus Champion Hospitals in Bangalore for a total cost of Rs 1,650 million. The target company, which operates a 125-bed facility, reported a turnover of Rs 274.90 million in FY25. Apollo plans to invest a total of Rs 3,000 million to upgrade and expand the facility to 175 beds. The revamped multi-speciality hospital is scheduled to reopen by Q1 FY27, strengthening Apollo's footprint in the Bangalore healthcare market.
முக்கிய அம்சங்கள்
Acquired 100% stake in Belenus Champion Hospitals for a total consideration of Rs 1,650 million including liabilities.Target company reported FY25 revenue of Rs 274.90 million compared to Rs 305.84 million in FY24.Total project cost of Rs 3,000 million earmarked for acquisition and expansion to a 175-bed facility.The hospital is currently being upgraded and is expected to be operational by Q1 FY27.Acquisition executed through a 90% owned subsidiary, making Belenus a step-down subsidiary of Apollo Hospitals.
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the facility upgrade as this acquisition strengthens Apollo's presence in the high-demand Bangalore market. The long-term value will depend on the successful turnaround and scaling of the 175-bed facility by FY27.
Apollo Hospitals Q3FY26 Standalone PAT up 12% YoY to ₹384 Cr; Declares ₹10 Interim Dividend
Apollo Hospitals reported a robust performance for Q3FY26 with standalone revenue growing 15% YoY to ₹2,364 crore. Standalone EBITDA increased by 16% YoY to ₹594 crore, while Profit After Tax rose 12% to ₹384 crore, despite a one-time exceptional charge of ₹11.4 crore related to new labour codes. The Board has declared an interim dividend of ₹10 per share (200% of face value) with a record date of February 16, 2026. The company is also progressing with its strategic restructuring to demerge its pharmacy and digital health businesses.
முக்கிய அம்சங்கள்
Standalone Revenue from operations grew 15% YoY to ₹23,637 million compared to ₹20,548 million in Q3FY25.Standalone EBITDA rose 16% YoY to ₹5,935 million from ₹5,118 million in the previous year.Interim dividend of ₹10 per share declared; Record date fixed as February 16, 2026.Profit After Tax (PAT) increased 12.3% YoY to ₹3,835 million despite an exceptional cost of ₹114 million.Company has filed an application with NCLT for the demerger of its pharmacy distribution and digital health platform.
👀 கவனிக்க வேண்டியவை
Investors should take note of the steady double-digit growth across key financial metrics and the healthy dividend payout. The upcoming demerger of the pharmacy and digital health business remains a key monitorable for long-term value unlocking.
Apollo Tyres Q3 FY26: Record Revenue of ₹77.4B and ₹5,800 Cr Capex Plan Announced
Apollo Tyres reported its highest-ever quarterly consolidated revenue of INR 77.4 billion, marking a 12% YoY growth driven by robust double-digit volume growth in India. The company achieved significant deleveraging, with net debt falling to INR 13 billion from INR 26 billion in the previous quarter, resulting in a Net Debt/EBITDA of 0.4x. A major expansion plan of INR 5,800 crore was approved for the Andhra Pradesh plant to be spent over FY27-29 to address high capacity utilization. While India margins were slightly impacted by BCCI sponsorship costs, European margins remained resilient at 17.9%.
முக்கிய அம்சங்கள்
Consolidated revenue reached a record INR 77.4 billion, up 12% YoY with consolidated EBITDA margins at 15.3%.Net debt reduced by 50% in one quarter to INR 13 billion, driven by strong operational cash flows.Approved INR 5,800 crore capex for AP plant expansion (PCR and TBR) to be executed over the next three financial years.India volume growth was in mid-teens for OEM and replacement segments, while exports grew nearly 20%.European operations saw premiumization gains with the Ultra High Performance (UHP) mix rising to 52%.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's aggressive debt reduction and the start of a new growth capex cycle which signals management's confidence in long-term demand. The temporary margin pressure from branding spends is expected to normalize by FY27, making this a strong pick for long-term growth.
Apollo Micro Systems Reports Zero Deviation in Utilization of Rs 185.13 Cr Fundraise
Apollo Micro Systems has confirmed zero deviation in the utilization of proceeds from its preferential issue for the quarter ended December 31, 2025. During the quarter, the company received Rs 185.13 crore, representing 75% of the warrant application money for 2.16 crore share warrants. These funds remained unutilized as of the quarter-end due to pending listing approvals from the stock exchanges. The total estimated proceeds from the preferential issue have been revised to Rs 742.25 crore, with major allocations toward working capital and R&D.
முக்கிய அம்சங்கள்
Confirmed zero deviation or variation in the use of funds raised via preferential issue.Received Rs 185.13 crore during Q3 FY26 as 75% warrant application money for 2,16,52,792 warrants.Total issue proceeds revised to Rs 74,225 Lakhs (Rs 742.25 Cr) from an original estimate of Rs 81,608 Lakhs.Rs 185.13 crore remains unutilized as of Dec 31, 2025, pending listing approvals from BSE and NSE.Primary fund allocation includes Rs 454.77 Cr for working capital and Rs 68.21 Cr for R&D expenditure.
👀 கவனிக்க வேண்டியவை
Investors should track the deployment of the unutilized Rs 185.13 crore once listing approvals are secured, as it will support the company's working capital and R&D initiatives. The lack of deviation indicates disciplined capital management by the board.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Apollo Micro Systems Reports Record Q3 FY26 Revenue and Expansion into Defence Explosives
Apollo Micro Systems delivered its highest-ever quarterly and nine-month revenue for the period ending December 31, 2025. The company is successfully transitioning from a subsystem provider to a complete weapon systems manufacturer, indigenizing critical technologies like underwater mines and torpedo homing systems. A major strategic milestone includes securing licenses for manufacturing high-energy explosives (HMX and TNT) with capacities of 50 MTPA and 500 MTPA respectively. Furthermore, the company is advancing into Directed Energy Weapons (DEW) and Unmanned Aerial Systems, significantly broadening its addressable market within the Indian defence sector.
முக்கிய அம்சங்கள்
Achieved highest ever revenue for both Q3 FY26 and the 9-month period ending December 2025Secured manufacturing licenses for 50 MTPA of HMX and 500 MTPA of TNT explosives valid for 15 yearsCompany accounts for approximately 60% of electronics and mechanical systems in indigenized missile programsOnly Indian company offering a complete range of Shallow Water, Deep Water, and Limpet Under Water MinesTrials for Vehicle Mounted Counter Drone Systems (VMCSDS) scheduled to initiate in Q1 FY27
👀 கவனிக்க வேண்டியவை
Investors should consider the company's transition to high-value complete weapon systems and its entry into the explosives market as strong catalysts for margin expansion. Monitor the progress of the Unit-III facility and the upcoming trials for counter-drone systems in early FY27.
Apollo Micro Systems Q3 Revenue Surges 70% YoY to ₹252 Cr; PAT Up 25%
Apollo Micro Systems reported its highest-ever quarterly revenue of ₹252.2 crore for Q3FY26, representing a significant 70% YoY growth. The 9-month performance was equally strong, with PAT rising 67% YoY to ₹70.6 crore and EBITDA margins expanding by 134 bps. Management has provided a robust growth guidance of 45-50% CAGR over the next three years, backed by a healthy order book of ₹1,305 crore. However, investors should note that EPS growth was tempered by equity dilution from preference share issuances.
முக்கிய அம்சங்கள்
Q3FY26 Revenue surged 70% YoY to ₹252.2 crore, driven by robust order book execution.9MFY26 PAT grew 67% YoY to ₹70.6 crore with a solid order book standing at ₹1,305 crore.Management projects a 45-50% CAGR for the core business over the next three years.EBITDA for Q3 rose 33% YoY to ₹50.4 crore, though Q3 margins (20%) were lower than Q2 (26.3%).An additional acquisition by subsidiary ADIPL is expected to be completed by the end of FY26.
👀 கவனிக்க வேண்டியவை
The strong revenue growth and aggressive multi-year guidance make this a positive update for long-term investors in the defense electronics sector. Monitor the impact of equity dilution on EPS and the integration of upcoming acquisitions.
Apollo Tyres Q3 FY26: Revenue up 12%, EBITDA Jumps 25% with Record India Sales
Apollo Tyres reported a strong Q3 FY26 with consolidated revenue growing 11.8% YoY to ₹77,431 Mn and EBITDA rising 25.2% to ₹11,859 Mn. The India business achieved its highest-ever quarterly revenue, crossing the ₹5,000 Cr mark, driven by pent-up demand and GST rate reductions. While European demand remained muted, margins improved slightly to 17.9% due to a higher mix of Ultra High Performance (UHP) tyres. Notably, the company significantly reduced its net debt by ₹13 Bn during the quarter, bringing the Net Debt/EBITDA ratio down to 0.4x.
முக்கிய அம்சங்கள்
Consolidated revenue grew 11.8% YoY to ₹77,431 Mn, while EBITDA margins expanded by 165 bps to 15.3%.India operations saw record quarterly revenue of ₹51,390 Mn, marking the highest YoY growth in 12 quarters.Net debt decreased by ₹13 Bn in Q3, resulting in a healthy Net Debt/EBITDA ratio of 0.4x.European operations maintained margins at 17.9% despite flattish revenue, supported by a 52% UHP tyre mix.YTD Free Cash Flow surged to ₹16 Bn compared to ₹3 Bn in the previous full year.
👀 கவனிக்க வேண்டியவை
Investors should view the significant debt reduction and record India performance as strong indicators of financial health and operational efficiency. The stock remains a key play in the tyre sector given its improving premium mix and robust cash flow generation.
Apollo Tyres to Invest ₹5,810 Cr for Capacity Expansion; Declares ₹3.50 Interim Dividend
Apollo Tyres has announced a major capacity expansion at its Andhra Pradesh plant with a total investment of ₹5,810 crore, aimed at adding 3.7 million PCR and 1.3 million TBR tyres per annum by FY29. The company reported strong Q3 FY26 results with consolidated revenue reaching ₹77,430.77 million and a profit of ₹4,705.18 million. Additionally, the board has declared an interim dividend of ₹3.50 per share, rewarding shareholders amid growth plans. The expansion is driven by high current utilization levels of 82% in PCR and 89% in TBR segments.
முக்கிய அம்சங்கள்
Investment of ₹5,810 crore planned for capacity expansion in Andhra Pradesh by the end of FY2029.Proposed addition of 3.7 million Passenger Car Radial (PCR) and 1.3 million Truck Bus Radial (TBR) tyres per annum.Q3 FY26 consolidated revenue grew to ₹77,430.77 million compared to ₹69,279.54 million in the previous year.Interim dividend of ₹3.50 per equity share declared with a record date of February 10, 2026.Expansion to be funded through a mix of internal accruals and debt to meet healthy medium-term demand.
👀 கவனிக்க வேண்டியவை
The significant capex indicates strong demand visibility and long-term growth prospects; investors should hold for the expansion cycle while monitoring the impact of new debt on the balance sheet.
Apollo Pipes Targets Strong Q4 Recovery; Varanasi Plant to Start in March 2026
Apollo Pipes reported flat sales volumes for 9M FY26 due to industry headwinds like PVC price volatility and weak Agri demand, though the housing segment grew by 10%. Management is optimistic about a strong Q4, targeting 32,000-35,000 tons to achieve high single-digit full-year growth. The company is expanding its footprint with the upcoming Varanasi plant and focusing on high-margin CPVC products through a Lubrizol tie-up. Despite elevated inventory levels of 80 days, the company remains committed to reaching a 2,86,000-ton capacity without adding debt.
முக்கிய அம்சங்கள்
Targeting Q4 FY26 sales volume of 32,000-35,000 tons to reach ~107,000 tons for the full year.Housing segment (60% of revenue) grew 10% Y-o-Y, offsetting declines in Agri and HDPE segments.Varanasi plant on track to commence operations in March 2026 to strengthen Eastern India presence.Incurred ₹125 crore CAPEX in 9M FY26 as part of a plan to reach 2,86,000 tons capacity in 2 years.Inventory levels stood at 80 days in December 2025, with a target to reduce to 60 days by Q4 end.
👀 கவனிக்க வேண்டியவை
Investors should monitor the successful commissioning of the Varanasi plant and the management's ability to reduce inventory levels in Q4. The shift toward a 70-75% housing portfolio mix is a positive long-term strategy for margin improvement.
Apollo Pipes Q3 FY26: Revenue Drops 20% YoY to ₹247 Cr with a Net Loss of ₹3.3 Cr
Apollo Pipes reported a weak Q3 FY26, with revenue declining 20% YoY to ₹247.2 crore and a net loss of ₹3.3 crore compared to a profit of ₹6.2 crore in the previous year. EBITDA margins contracted significantly by 270 basis points YoY to 4.9%, driven by lower volumes and pricing pressures. Despite the poor quarterly performance, the company is expanding its capacity to 286,000 MTPA and has integrated Kisan Mouldings to drive long-term growth. Sales volumes showed a sequential recovery of 17% QoQ, though they remained 6% lower on a yearly basis.
முக்கிய அம்சங்கள்
Revenue fell 20% YoY to ₹247.2 crore, while 9M FY26 revenue declined 13% to ₹757.9 croreReported a Net Loss of ₹3.3 crore in Q3 FY26 against a Net Profit of ₹6.2 crore in Q3 FY25EBITDA margins shrunk to 4.9% from 7.6% YoY, with EBITDA falling 48% to ₹12.0 croreSales volume stood at 25,386 MT, a 6% YoY decline but a 17% sequential improvementCompany transitioned from a Net Cash position of ₹46 crore in FY25 to a Net Debt of ₹28 crore
👀 கவனிக்க வேண்டியவை
Investors should remain cautious due to the sharp margin erosion and the shift into a net loss position. Monitor the integration of Kisan Mouldings and the ramp-up of the new Varanasi plant for signs of operational recovery.
Apollo Pipes Reports Q3 FY26 Net Loss of ₹2.64 Cr; Revenue Declines 19.7% YoY
Apollo Pipes Limited reported a consolidated net loss of ₹2.64 crore for the quarter ended December 31, 2025, a significant decline from a profit of ₹5.21 crore in the previous year's corresponding quarter. Revenue from operations fell to ₹247.18 crore from ₹307.93 crore YoY, reflecting a challenging demand environment. The results were further weighed down by a ₹3.60 crore loss from its subsidiary, Kisan Moulding Limited, and a one-time provision of ₹1.27 crore for new labour codes. On a positive note, the company confirmed that its new Mirzapur manufacturing plant is expected to commence production by the end of FY26.
முக்கிய அம்சங்கள்
Consolidated revenue from operations decreased 19.7% YoY to ₹247.18 crore in Q3 FY26.Reported a consolidated net loss of ₹2.64 crore compared to a profit of ₹5.21 crore in Q3 FY25.Subsidiary Kisan Moulding Limited reported a net loss of ₹3.60 crore for the quarter.New manufacturing plant at Mirzapur, UP, is on track for commissioning by the end of FY26.Recognized a provision of ₹1.27 crore towards incremental liability for new Labour Codes.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to turnaround the Kisan Moulding subsidiary and the timely execution of the Mirzapur plant. The current swing to a loss and declining revenue suggest short-term pressure on the stock.
CRISIL Revises Apollo Hospitals' Outlook to 'Positive'; Reaffirms 'AA+' Rating
CRISIL Ratings has revised the outlook on Apollo Hospitals Enterprise Ltd (AHEL) to 'Positive' from 'Stable' while reaffirming its 'CRISIL AA+' rating. This revision reflects AHEL's dominant market position as India's largest private healthcare provider and expectations of sustained mid-teen revenue growth. The company is projected to achieve consolidated revenues of over Rs. 24,000 crores in fiscal 2026 with healthy EBITDA margins of 23-24% post-demerger of its pharmacy business. Despite a planned capex of Rs. 6,000 crore for bed expansion, the company maintains a robust financial profile with a cash surplus of Rs. 3,222 crore.
முக்கிய அம்சங்கள்
Long-term rating outlook revised to 'Positive' from 'Stable'; 'CRISIL AA+' rating reaffirmed.Consolidated revenue estimated to grow 12-15% YoY to over Rs. 24,000 crores in fiscal 2026.Planned capex of ~Rs. 6,000 crore to add 3,600+ beds over the next 3-5 years.Strong liquidity position with cash and cash equivalents of Rs. 3,222 crore as of September 30, 2025.Debt/EBITDA estimated at 1.65x for FY26, with expectations to drop below 1.5x by FY27.
👀 கவனிக்க வேண்டியவை
The outlook revision to 'Positive' indicates a potential rating upgrade in the medium term, reflecting strong operational cash flows and market leadership. Investors should view this as a sign of high credit quality and financial stability as the company executes its massive bed expansion plan.
Apollo Tyres to Consider Interim Dividend for FY26; Record Date Set for Feb 10, 2026
Apollo Tyres has scheduled a board meeting on February 4, 2026, to consider the declaration of an interim dividend for the financial year 2025-26. The company has established February 10, 2026, as the record date to determine eligible shareholders for the payout. Tax Deduction at Source (TDS) will be applied at 10% for resident shareholders with a valid PAN, while a 20% rate applies to those without. Notably, no TDS will be deducted for resident individuals if the total dividend for the fiscal year does not exceed ₹10,000.
முக்கிய அம்சங்கள்
Board meeting to consider FY26 interim dividend scheduled for February 4, 2026Record date for dividend eligibility fixed as February 10, 2026Standard TDS rate of 10% for residents with PAN and 20% for those without/invalid PANTDS exemption for resident individuals if total FY26 dividend is ₹10,000 or lessDeadline for submitting tax exemption documents (Form 15G/15H) is February 11, 2026
👀 கவனிக்க வேண்டியவை
Investors should ensure their PAN and bank account details are updated with their DP or RTA to avoid higher tax deductions. Eligible shareholders should submit tax exemption forms like 15G or 15H by the February 11 deadline.
APL Apollo Upgrades EBITDA Guidance to ₹5,500/Ton; Targets 8MT Capacity by FY28
APL Apollo Tubes reported a strong 3QFY26 performance, achieving 9-month volume growth of 11% YoY and EBITDA per ton exceeding ₹5,000. Management has upgraded its sales volume growth guidance to 20% for 4QFY26 and FY27, alongside an increased EBITDA target of ₹5,500 per ton. The company is aggressively expanding capacity from 5 million to 8 million tons by FY28 with a ₹1,500 crore investment funded through internal accruals. With a cash surplus of ₹5.6 billion, the firm is on track to become liability-free while targeting a 40% ROCE.
முக்கிய அம்சங்கள்
Upgraded EBITDA guidance to ₹5,500 per ton for 4QFY26 and FY27, driven by premiumization and cost controls.Capacity expansion to 8 million tons by FY28 via 4 greenfield and 1 brownfield project costing ₹1,500 crores.Achieved 90% utilization in December 2025 with monthly sales hitting 375,000 tons.Long-term vision to reach 10 million tons capacity by 2030, including 2 million tons in super-specialty segments.Strong financial position with ₹5.6 billion surplus cash and current ROCE of 33%.
👀 கவனிக்க வேண்டியவை
Investors should note the significant upgrade in EBITDA guidance and aggressive volume targets which signal strong pricing power. The company's transition to a liability-free balance sheet and expansion into high-margin specialty segments like EV and aerospace provides a positive long-term outlook.
Apollo Tyres Board Meeting on Feb 4 to Consider Q3 Results and Interim Dividend
Apollo Tyres Limited has scheduled a Board of Directors meeting for February 4, 2026, to review and approve the un-audited financial results for the quarter and nine-month period ending December 31, 2025. In addition to financial results, the board will consider the declaration of an interim dividend for the financial year 2025-26. The company has proactively set February 10, 2026, as the record date for the dividend payment, contingent on board approval. The trading window for company securities remains closed until February 6, 2026.
முக்கிய அம்சங்கள்
Board meeting scheduled for February 4, 2026, to approve Q3 and nine-month FY26 results.Proposal for an interim dividend for FY26 to be considered during the meeting.Record date for the potential interim dividend is fixed as February 10, 2026.Trading window for insiders is closed from January 1 to February 6, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor the February 4 results for margin trends and the specific dividend amount declared. To be eligible for the dividend, shares must be held before the February 10 record date.
APL Apollo Q3FY26: Net Profit Surges 43% YoY to ₹3.1 Bn on Record Sales Volume
APL Apollo Tubes reported a strong Q3FY26 performance with its highest-ever quarterly sales volume of 917k tons, an 11% YoY increase. Net profit jumped 43% YoY to ₹3.1 billion, supported by a significant 37% growth in EBITDA which reached ₹4.7 billion. The company maintains a robust financial position with a net cash balance of ₹5.6 billion and an annualized ROCE of 33.3% for 9MFY26. Management has also outlined an ambitious roadmap to double its annual capacity to 10 million tons by FY30.
முக்கிய அம்சங்கள்
Record quarterly sales volume of 917k tons, up 11% YoY and 7% QoQ.EBITDA per ton improved 23% YoY to ₹5,146, driven by a 57% value-added product mix.Net profit increased 43% YoY to ₹3.1 billion, while revenue grew 7% YoY to ₹58.2 billion.Strong balance sheet with net cash of ₹5.6 billion and net working capital cycle of just 3 days.Announced ₹13 billion capex plan by FY28 to reach 7 million tons, targeting 10 million tons by FY30.
👀 கவனிக்க வேண்டியவை
Investors should view the record volumes and improving margins as a sign of strong market leadership and operational efficiency. The clear roadmap to double capacity by FY30 provides long-term growth visibility, making it a key stock to watch in the structural steel space.
APL Apollo Q3 FY26 Net Profit Jumps 43% YoY to ₹310 Cr; Revenue Up 7%
APL Apollo Tubes reported a strong performance for Q3 FY26, with consolidated net profit rising 43% year-on-year to ₹310.04 crore. Revenue from operations grew by 7% YoY to ₹5,811.13 crore, supported by improved operational efficiencies. The company's operating margin expanded significantly to 8.11% from 6.36% in the same quarter last year. For the nine-month period ended December 2025, net profit saw a massive surge of 83% YoY, reaching ₹848.75 crore.
முக்கிய அம்சங்கள்
Consolidated Net Profit increased 42.9% YoY to ₹310.04 crore in Q3 FY26Revenue from operations grew 7% YoY to ₹5,811.13 crore compared to ₹5,432.73 crore in Q3 FY25Operating margins improved to 8.11% in Q3 FY26 from 6.36% in the year-ago periodNine-month (9M FY26) net profit surged 83% YoY to ₹848.75 crore from ₹463.95 croreMaintains a strong net-cash position with a negative debt-equity ratio of -0.11
👀 கவனிக்க வேண்டியவை
The significant margin expansion and robust profit growth highlight APL Apollo's market leadership and operational efficiency. Investors should view this as a positive signal for the company's ability to scale profitability even with moderate revenue growth.
Apollo Hospitals gets CCI nod to acquire 30.58% stake in AHLL for Rs 12,540.68 million
Apollo Hospitals Enterprise Limited has received approval from the Competition Commission of India (CCI) to acquire a 30.58% equity stake in its subsidiary, Apollo Health and Lifestyle Limited (AHLL). The acquisition involves purchasing 41,650,368 equity shares from the International Finance Corporation (IFC) and IFC EAF for a total consideration of Rs 12,540.68 million. This move consolidates Apollo's ownership in its retail healthcare arm, which includes clinics, diagnostics, and primary care. The transaction follows the initial board approval granted in September 2025.
முக்கிய அம்சங்கள்
CCI approved the acquisition of 41,650,368 equity shares (30.58% stake) in AHLL.The total purchase consideration for the stake is Rs 12,540.68 million.The stake is being acquired from International Finance Corporation (IFC) and IFC EAF Apollo Investment Company.This acquisition increases Apollo's control over its high-growth retail healthcare and diagnostics business.
👀 கவனிக்க வேண்டியவை
Investors should view this consolidation of a key subsidiary as a positive long-term move for earnings accretion. Monitor the impact on the company's cash flow and the subsequent growth trajectory of the AHLL segment.
Apollo Micro Systems to Invest ₹300 Cr in New Hyderabad Weapon Systems Facility
Apollo Micro Systems (AMS) has been allotted 22,988 sq. mts of land in Hyderabad for ₹27.59 crores to establish a greenfield manufacturing unit. The company plans a total investment of ₹300 crores to create an integrated facility for manufacturing and testing weapon systems like Grad Rockets and Anti-Tank Mines. This expansion will double the company's footprint at the location to 10.68 acres by adjoining existing facilities. This move strengthens AMS's position as a Tier-I defense manufacturer under the 'Atmanirbhar Bharat' framework.
முக்கிய அம்சங்கள்
Acquisition of 22,988 sq. mts land at ₹12,000 per sq. mt, totaling ₹27.59 crores.Planned CAPEX of approximately ₹300 crores for manufacturing, assembly, and testing of defense platforms.Product focus includes Grad Rockets, Anti-Submarine Warfare Rockets, Anti-Tank Mines, and Artillery Munitions.Strategic expansion creates a unified 10.68-acre campus by adjoining existing upcoming facilities.Project stems from an MoU signed with the Telangana Government during the 'Telangana Rising Global Summit 2025'.
👀 கவனிக்க வேண்டியவை
This is a significant scale-up for AMS, indicating strong growth visibility and a shift toward complex weapon systems. Long-term investors should monitor the project's commissioning timeline and the funding structure for this ₹300 crore investment.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
